Similar immunogenicity of measles-mumps-rubella (MMR) vaccine administrated at 8 months versus 12 months age in children.
Two doses of measles-mumps-rubella (MMR) strategy has been recommended by World Health Organization and is also widely adopted in many countries. In order to provide the evidence for perfecting the immunization strategy of MMR, this study evaluated the safety and immunogenicity of MMR with different two-dose schedule in infants. 280 participants were enrolled and randomly allocated to Group 1 (first dose at 8 months) or Group 2 (first dose at 12 months), and both groups administered the second dose at 10 months later. Solicited local and general symptoms after each vaccination with MMR were mild and infrequent in all participants of two groups. After administration of the first dose of MMR, seropositive rates were 100% in both groups for measles, 89.3% in Group 1 and 87.1% in Group 2 for mumps (P=0.578), 92.0% in Group 1 and 92.9% in Group 2 (P=0.393). The seropositive rates of mumps decreased significantly (from >86% to <65%) both in two groups (P<0.001) 10 months after the first dose of MMR, but no significant change was found in measles and rubella. All children get the positive titer for three vaccines in two groups after given the second dose MMR, higher seroconversion rate was found for mumps both in two groups (71.7% vs 77.2%, P=0.370). In conclusion, this study indicated that the MMR was well tolerated and immunogenic against measles, mumps and rubella with schedule of first dose both at 8 months and 12 months age. Our findings strongly supported that two doses of MMR can be introduced by replacing the first dose of MR in current EPI with MMR at 8 months age and the second dose at 18 months in China.
Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, PR China. Electronic address: hhqcdc@gmail.com.
Hanqing
H
He
Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, PR China.
Enfu
E
Chen
China National Pharmaceutical Group Corporation, Beijing 100088, PR China.
Haiping
H
Chen
Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, PR China.
Zhifang
Z
Wang
Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, PR China.
Qian
Q
Li
Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, PR China.
Rui
R
Yan
Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, PR China.
Jing
J
Guo
Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, PR China.
Yang
Y
Zhou
Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, PR China.
Jinren
J
Pan
Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, PR China. Electronic address: Shyxie@cdc.zj.cn.
Shuyun
S
Xie
D000914:Antibodies, Viral / Q000097:blood; D002681:China; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D008457:Measles / Q000517:prevention & control; D022542:Measles-Mumps-Rubella Vaccine / Q000008:administration & dosage*; D009107:Mumps / Q000517:prevention & control; D012409:Rubella / Q000517:prevention & control
D000914:Antibodies, Viral; D022542:Measles-Mumps-Rubella Vaccine
Immunogenicity; Measles–mumps–rubella vaccine; Safety